Gilead Sciences, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 10.37 B

Gilead Sciences, Inc. Operating Cash Flow is USD 10.37 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 22.23% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Gilead Sciences, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 8.48 B, a -5.51% change year over year.
  • Gilead Sciences, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 8.98 B, a -15.43% change year over year.
  • Gilead Sciences, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 10.61 B, a 13.62% change year over year.
  • Gilead Sciences, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 9.34 B, a 3.77% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities